ClinicalTrials.gg
RecruitingNCT04999553LeRNITUpdated Aug 25, 2026

Left vs. Right Non-Inferiority Trial

An interventional study of Repetitive Transcranial Magnetic Stimulation and Intermittent Theta Burst Stimulation (iTBS) in Depression, Major Depressive Disorder and Major Depressive Episode, sponsored by University of British Columbia. Recruiting at 2 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Depression by University of British Columbia — 9 open to participants now, 10 under way, 1 of them phase 3. Depression · University of British Columbia.

Planned enrollment
3rd of 34
480 · median 76
Started
2021
with 2 others
No phase
25 of 34
6 open now
Registered
22nd of 34
by date

Among the 34 studies in Depression by University of British Columbia, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2021, is one of 25 with no phase, and was the 22nd registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

9 of the 34 studies in Depression by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Depression by University of British Columbia, or all of them as a file.
02

Study summary

The aim of this study is to test the hypothesis that low-frequency rTMS (LFR) works as well as the established intermittent thetaburst rTMS (iTBS) treatment for treatment resistant depression (TRD).

Read the detailed description

In this multi-centre, triple-blinded, non-inferiority trial 420 patients with TRD will be recruited at two academic centres (UBC, CAMH). Patients will be randomised to receive either iTBS or LFR for 30 sessions. The primary outcome will be the improvement on a depression scale. Secondary outcome will be improvement of suicidal ideation. A secondary aim is to test the predictive capacity of a novel, easy to implement heart rate based biomarkers (i.e. heart rate variability).

03

Conditions studied

  • Depression
  • Major Depressive Disorder
  • Major Depressive Episode

Keywords

  • rTMS
  • TMS
  • Transcranial Magnetic Stimulation
  • iTBS
  • Depression
  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. are female or male;
  2. are outpatients;
  3. are voluntary and competent to consent to treatment;
  4. have a DSM 5 diagnosis of MDD,55 single or recurrent confirmed by Mini-International Neuropsychiatric Interview (MINI) version 7.0;
  5. are 18yo to 65yo;
  6. have failed to achieve a clinical response to an adequate dose of an antidepressant based on an Antidepressant Treatment History Form (ATHF) score of > 3 in the current episode OR have been unable to tolerate at least two separate trials of antidepressants at less than the minimum adequate dose and/or duration (ATHF 1 or 2);
  7. have a score ≥ 18 on the Hamilton Depression Rating Scale (HDRS-17 item);
  8. have had no increase or initiation of any psychotropic medication in the 4 weeks prior to screening;
  9. are able to adhere to the treatment schedule;
  10. pass the TMS and MRI adult safety screening questionnaires.

Exclusion criteria

Exclusion Criteria:

  1. have a history of substance use within the last 3 months;
  2. have a concomitant major unstable medical illness;
  3. have active suicidal intent;
  4. are pregnant;
  5. have a lifetime (MINI) diagnosis of any psychotic or bipolar disorder;
  6. have a MINI anxiety disorder or personality disorder assessed by a study investigator to be primary and causing greater impairment than MDD;
  7. have failed a course of ECT in the current episode;
  8. have any significant neurological disorder, any history of seizure (except those therapeutically induced by ECT), significant head trauma with loss of consciousness for > 5 min;
  9. have any intracranial implant (e.g., aneurysm clips) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed;
  10. are participating in psychotherapy, must have been in stable treatment for at least 3 months prior to study entry, with no anticipated change in the frequency of therapeutic sessions, or focus of therapeutic sessions over the duration of the study;
  11. have a laboratory abnormality, in the opinion of the one of the principal investigators;
  12. have a non-correctable clinically significant sensory impairment (i.e., cannot hear well enough to cooperate with interview);
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
480 participants (estimated)

Study arms

  • Active comparator
    Intermittent Theta Burst Stimulation (iTBS)

    iTBS to the L-DLPFC

    Device: Repetitive Transcranial Magnetic Stimulation · Device: Intermittent Theta Burst Stimulation (iTBS)

  • Active comparator
    Low Frequency Right (LFR)

    1Hz stimulation to the R-DLPFC

    Device: Repetitive Transcranial Magnetic Stimulation · Device: Low Frequency Right (LFR)

Interventions

  • DeviceRepetitive Transcranial Magnetic Stimulation

    rTMS will employ the MagPro X100/R30 stimulator equipped with the cool-B70 as we used a cool-B70 in our past non-inferiority trial. The dose will be a 120% rMT in accordance to our latest trial using iTBS. The target area to stimulate will be the right dorsolateral prefrontal cortex (DLPFC) for LFR and the left DLPFC for iTBS as established in prior clinical trials. The localization of both targets will follow the well-established procedures for either R-DLPFC or L-DLPFC using a heuristic method.

  • DeviceIntermittent Theta Burst Stimulation (iTBS)

    Intermittent Theta Burst Stimulation (iTBS)

  • DeviceLow Frequency Right (LFR)

    Low Frequency Right (LFR)

06

What researchers measure

Primary outcomes

  1. Depression severity

    17 item Hamilton Depression Rating Scale (HDRS-17) Change

    Time frame: 30 days

Secondary outcomes

  1. Suicidal ideation

    Columbia Suicide Severity Rating Scale Screen Version (C-SSRS) Change

    Time frame: 30 days

  2. Anxiety severity

    Hamilton Anxiety Rating Scale (HAM-A) Change

    Time frame: 30 days

  3. Depression severity

    Self-rated 16-item Quick Inventory of Depressive Symptoms (QIDS-16) Change

    Time frame: 30 days

07

Study locations

2 of 2 sites recruiting
  • Non-Invasive Neurostimulation Therapies Centre, University of British Columbia
    Vancouver, British Columbia V6T 2A1, Canada
    Recruiting
    • Amanda Ding · Contactninet.lab@ubc.ca · 6048221361
    • Fidel Vila-Rodriguez, MD, PhD · Principal investigator
  • Centre for Addiction and Mental Health
    Toronto, Ontario M6J 1H4, Canada
    Recruiting
    • Stacey Shim, MSc · ContactStacey.Shim@camh.ca · 416-535-8501
    • Daniel Blumberger, MD, MSc · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Jun 2027, 66 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 66 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2021
First posted
Aug 11, 2021
StartActual
Nov 8, 2021
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04999553
Responsible party
Fidel Vila-Rodriguez, MD, PhD, FRCPC, DFAPA (Principle Investigator, University of British Columbia) — Principal investigator
First posted
Aug 11, 2021
Start date
Nov 8, 2021
Primary completion
Jun 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Aug 25, 2026

Study contacts

Amanda Ding
Contact
ninet.lab@ubc.ca
604-827-1361
Fidel Vila-Rodriguez, MD, PhD
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion